Table V.
Effect of the CYP3A5*3 genotype on amlodipine plasma concentration (C) and efficacy.
| Genotype | P-value | ||||||
|---|---|---|---|---|---|---|---|
| Variables | AA (n=7) | AG (n=24) | GG (n=29) | AA vs. AG | AA vs. GG | AG vs. GG | ANOVA |
| C, ng/ml | |||||||
| C0 | 4.82±2.05 | 7.88±4.17 | 6.77±2.92 | 0.095 | 0.130 | 0.262 | 0.137 |
| C2 | 6.70±2.93 | 9.91±4.86 | 8.57±3.38 | 0.109 | 0.189 | 0.242 | 0.156 |
| C6 | 7.81±4.27 | 12.07±5.56 | 10.35±3.54 | 0.073 | 0.110 | 0.198 | 0.083 |
| C24 | 4.99±2.97 | 7.96±3.85 | 6.10±3.16 | 0.070 | 0.405 | 0.059 | 0.062 |
| BP, mmHg | |||||||
| Δ SBP | 20±5 | 19±10 | 16±11 | 0.695 | 0.169 | 0.332 | 0.483 |
| Δ DBP | 10±4 | 8±7 | 6±5 | 0.440 | 0.096 | 0.355 | 0.290 |
| Efficiency, % | 85.71 | 50.00 | 48.28 | 0.092 | 0.074 | 0.901 | 0.187 |
CYP, cytochrome P450; ANOVA, analysis of variance; C0, C at 4 weeks; C2, 2 h after the last dose at 4 weeks; C6, 6 h; C24, 24 h; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.